Loading clinical trials...
Loading clinical trials...
A Phase 2B/3 Prospective, Randomized, Double-Blind, Sham-Controlled Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease
Conditions
Interventions
Adrabetadex
Locations
30
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Children's Hospital of Orange County: CHOC Children's
Orange, California, United States
University of California San Francisco
San Francisco, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
Shands Children's Hospital
Gainesville, Florida, United States
Start Date
December 23, 2015
Primary Completion Date
April 11, 2022
Completion Date
April 11, 2022
Last Updated
August 29, 2023
NCT03879655
NCT01306604
NCT03887533
NCT02939547
NCT00975689
Lead Sponsor
Mandos LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions